If approved, the Opdivo-based regimen would be the first immunotherapy-chemotherapy combination approved for this patient population in the EU
Laurus Labs has reported total income of Rs. 1,458.20 crores during the period ended March 31, 2024
The proposed facility is expected to be operational around January, 2027
The joint venture will help JV Partners combine their strengths and grow their complementary nutraceuticals portfolios
Sales reflect continued strong growth in oncology and vaccines
Syngene International has reported total income of Rs. 933 crores during the period ended March 31, 2024
The campaign marks an important milestone in its journey within the pharmaceutical manufacturing industry
Breakthrough Therapy designation for pain associated with DPN granted by FDA
10th edition of the event is scheduled to be held during May 30-June 1 at Hitex, Hyderabad
Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine
Subscribe To Our Newsletter & Stay Updated
